Johnson & Johnson (JNJ)[Tv]

Key Developments

• FDA approval of icotrokinra (Icotyde) – The first-of-its-kind oral targeted peptide therapy for plaque psoriasis marks a transformative milestone in immunology, opening high-margin commercial pathways across psoriatic arthritis, ulcerative colitis, and Crohn’s disease with minimal near-term competition.
• Illinois Appellate Court upholds $45 million talc-related verdict – A unanimous ruling affirming liability against Johnson & Johnson dismantles the company’s legal strategy of using corporate restructuring to avoid responsibility, signaling a pivotal and devastating shift in judicial scrutiny of legacy product claims.
• FDA accepts sBLA for IMAAVY with Breakthrough Therapy Designation – This regulatory catalyst positions JNJ at the forefront of rare autoimmune therapeutics, with transformative growth potential in a high-unmet-need market and strong commercial scalability.
• CHMP recommends Tecvayli (with Darzalex) in relapsed/refractory multiple myeloma – A major clinical inflection point that could establish the regimen as a second-line standard of care in Europe if approved, enhancing JNJ’s oncology pipeline and commercial momentum.
• Revival of Tylenol-related lawsuits against Kenvue (former JNJ entity) – Federal appeals court decision reactivates legal exposure for JNJ despite the spin-off, raising serious concerns about legacy liability spillovers and reputational damage.